Alefacept-treated patients showing slower T1D progression (R) preserved higher CD57+ Tex levels following treatment than patients showing more rapid disease progression, consistent with a role for CD57+ Tex in suppression of autoimmunity. Here, B3GAT1 is linked to type 1 diabetes mellitus.